← Leaderboards
Lionel David Lewis
Dartmouth College
$6,297,534
Attributed
$8,629,801
Total exposure
13
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,629,801 · 13
By mechanism
R44$3,998,400 · 2
P30$3,950,321 · 10
U54$681,080 · 1
Top collaborators
- Upendra Marathi4 shared
- William Schary2 shared
Most similar at Dartmouth College
Same institution · by research overlap
- Steven D Leach$25,866,740
- Marnie E Halpern$11,070,639
- Amy E Keating$19,695,788
- David W Nierenberg$883,152
- Hany Farid$915,375
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchProtocols DocumentationClinical OncologyMemberCancer Center Support GrantNorris Cotton Cancer CenterMalignant NeoplasmsOncologyClinical PharmacologyProgramsDesignResearch PersonnelSafetyDrug KineticsCellsPre-ClinicalPlasmaMonitorClinical TrialsOncology GroupSamplingTumor TissueIn VivoData Analyses
Grant awards (61)
Protocol Review and Monitoring Systems$74,147
P30 · FY2025 · CA · contact PI
7HP349, an Integrin Activator to Treat Patients With anti-PD-1 Resistant Solid Tumors$999,200
R44 · FY2024 · CA
Clinical Pharmacology (CP)$109,940
P30 · FY2024 · CA · contact PI
Protocol Review and Monitoring System (PRMS)$70,984
P30 · FY2024 · CA · contact PI
Clinical Pharmacology (CP)$5,264
P30 · FY2024 · CA · contact PI
Protocol Review and Monitoring System (PRMS)$5,262
P30 · FY2024 · CA · contact PI
7HP349, an Integrin Activator to Treat Patients With anti-PD-1 Resistant Solid Tumors$999,200
R44 · FY2023 · CA
Clinical Pharmacology (CP)$109,938
P30 · FY2023 · CA · contact PI
Protocol Review and Monitoring System (PRMS)$70,986
P30 · FY2023 · CA · contact PI
Clinical Pharmacology (CP)$109,938
P30 · FY2022 · CA · contact PI
Protocol Review and Monitoring System (PRMS)$70,986
P30 · FY2022 · CA · contact PI
Development of 7HP349, an oral integrin activator to enhance therapeutic responses to immune checkpoint inhibitors$1,015,591
R44 · FY2021 · CA
Clinical Pharmacology (CP)$109,938
P30 · FY2021 · CA · contact PI
Protocol Review and Monitoring System (PRMS)$70,986
P30 · FY2021 · CA · contact PI
Development of 7HP349, an oral integrin activator to enhance therapeutic responses to immune checkpoint inhibitors$984,409
R44 · FY2020 · CA
Clinical Pharmacology (CP)$109,940
P30 · FY2020 · CA · contact PI
Protocol Review and Monitoring System (PRMS)$70,986
P30 · FY2020 · CA · contact PI
Clinical Pharmacology (CP)$118,217
P30 · FY2019 · CA · contact PI
Protocol Review and Monitoring (PRMS)$59,340
P30 · FY2019 · CA · contact PI
Clinical Pharmacology (CP)$119,153
P30 · FY2018 · CA · contact PI
Protocol Review and Monitoring (PRMS)$62,026
P30 · FY2018 · CA · contact PI
Protocol Review and Monitoring (PRMS)$6,057
P30 · FY2018 · CA · contact PI
Clinical Pharmacology (CP)$6,057
P30 · FY2018 · CA · contact PI
Protocol Review and Monitoring (PRMS)$5,342
P30 · FY2018 · CA · contact PI
Clinical Pharmacology (CP)$5,342
P30 · FY2018 · CA · contact PI
Clinical Pharmacology (CP)$4,791
P30 · FY2018 · CA · contact PI
Protocol Review and Monitoring (PRMS)$4,790
P30 · FY2018 · CA · contact PI
Clinical Pharmacology (CP)$3,213
P30 · FY2018 · CA · contact PI
Protocol Review and Monitoring (PRMS)$3,213
P30 · FY2018 · CA · contact PI
Clinical Pharmacology (CP)$1,667
P30 · FY2018 · CA · contact PI
Protocol Review and Monitoring (PRMS)$1,667
P30 · FY2018 · CA · contact PI
Clinical Pharmacology (CP)$121,368
P30 · FY2017 · CA · contact PI
Protocol Review and Monitoring (PRMS)$63,931
P30 · FY2017 · CA · contact PI
Clinical Pharmacology (CP)$1,822
P30 · FY2017 · CA · contact PI
Protocol Review and Monitoring (PRMS)$965
P30 · FY2017 · CA · contact PI
Clinical Pharmacology (CP)$120,598
P30 · FY2016 · CA · contact PI
Protocol Review and Monitoring (PRMS)$61,721
P30 · FY2016 · CA · contact PI
Clinical Pharmacology (CP)$118,217
P30 · FY2015 · CA · contact PI
Protocol Review and Monitoring (PRMS)$59,340
P30 · FY2015 · CA · contact PI
Toxicology, Pathology and Biodistribution Core (TPB Core)$158,492
U54 · FY2014 · CA · contact PI
CLINICAL PHARMACOLOGY SHARED RESOURCE$124,350
P30 · FY2014 · CA · contact PI
PROTOCOL REVIEW AND MONITORING SYSTEM$124,348
P30 · FY2014 · CA · contact PI
Toxicology, Pathology and Biodistribution Core (TPB Core)$159,823
U54 · FY2013 · CA · contact PI
CLINICAL PHARMACOLOGY SHARED RESOURCE$133,666
P30 · FY2013 · CA · contact PI
PROTOCOL REVIEW AND MONITORING SYSTEM$40,924
P30 · FY2013 · CA · contact PI
Toxicology, Pathology and Biodistribution Core (TPB Core)$174,166
U54 · FY2012 · CA · contact PI
CLINICAL PHARMACOLOGY SHARED RESOURCE$142,250
P30 · FY2012 · CA · contact PI
PROTOCOL REVIEW AND MONITORING SYSTEM$43,553
P30 · FY2012 · CA · contact PI
CLINICAL PHARMACOLOGY SHARED RESOURCE$141,565
P30 · FY2011 · CA · contact PI
Toxicology, Pathology and Biodistribution Core (TPB Core)$92,723
U54 · FY2011 · CA · contact PI
PROTOCOL REVIEW AND MONITORING SYSTEM$43,348
P30 · FY2011 · CA · contact PI
CLINICAL PHARMACOLOGY SHARED RESOURCE$161,212
P30 · FY2010 · CA · contact PI
Toxicology, Pathology and Biodistribution Core (TPB Core)$95,876
U54 · FY2010 · CA · contact PI
PROTOCOL REVIEW AND MONITORING SYSTEM$49,363
P30 · FY2010 · CA · contact PI
CLINICAL PHARMACOLOGY SHARED RESOURCE$151,412
P30 · FY2009 · CA · contact PI
PROTOCOL REVIEW AND MONITORING SYSTEM$46,361
P30 · FY2009 · CA · contact PI
Clinical Molecular$254,198
P30 · FY2008 · CA · contact PI
Clinical Molecular$239,560
P30 · FY2007 · CA · contact PI
Clinical Molecular$108,489
P30 · FY2006 · CA · contact PI
Clinical Molecular$105,330
P30 · FY2005 · CA
Clinical Molecular$102,260
P30 · FY2004 · CA